Johnson & Johnson raised its full-year earnings forecast for the second quarter in a row, reflecting improved procedure volumes and a steady drumbeat of new product launches in its medtech segment. The New Brunswick, New Jersey-based company now expects revenue of $98.8 billion to $99.8 billion for 2023, an increase from a previous range of $97.9 billion to $98.9 billion. J&J also predicts adjusted earnings per share of $10.70 to $10.80, a 6% increase year-over-year at the midpoint.
